Skip to content
Catalyst

phosphate(3-)What was measured

Measured, with no finding

318 endpoints

Show what was measuredHide what was measured
  • serum Ca, PO4, Zn, 1,25-(OH)2D3 and urinary beta-2-microglobulin

    no effect, n = 10

    There were no changes in serum levels of Ca, PO4 or Zn, in serum concentration of 1,25-(OH)2D3, and in urinary beta-2-microglobulin excretion

    PMID 11305263 · one of two readings recorded this

  • serum osteocalcin

    no effect, n = 10

    a decrease of 0.6+/-0.6 ng/ml in serum osteocalcin

    PMID 11305263 · one of two readings recorded this

  • serum PTH

    no effect, n = 10

    an increase of 10.7+/-13.7 pg/ml in serum PTH

    PMID 11305263 · one of two readings recorded this

  • urinary deoxypyridinoline

    no effect, n = 10

    of 19.3+/-36.0 nmol/ mmol creatinine in urinary deoxypyridinoline

    PMID 11305263 · one of two readings recorded this

  • urinary microalbumin

    no effect, n = 10

    a decrease of 2.6+/-9.3 mg/l in urinary microalbumin

    PMID 11305263 · one of two readings recorded this

  • urinary pyridinoline

    no effect, n = 10

    an increase of 73.6+/-136.6 nmol/mmol creatinine in urinary pyridinoline

    PMID 11305263 · one of two readings recorded this

  • serum 1,25-dihydroxycholecalciferol

    no effect

    serum 1,25-dihydroxycholecalciferol remained unchanged

    PMID 1422972 · one of two readings recorded this

  • serum bone alkaline phosphatase

    no effect

    no significant changes were observed in urinary hydroxyproline/creatinine ratio, or serum bone alkaline phosphatase

    PMID 1422972 · one of two readings recorded this

  • serum calcium

    no effect

    no significant changes were seen in serum phosphate or serum calcium

    PMID 1422972 · one of two readings recorded this

  • serum osteocalcin (mean)

    increases, p = 0.05

    In the group receiving 1500 mg/day, mean serum osteocalcin was increased in the period from day 1 to day 28 (P less than 0.05)

    PMID 1422972 · one of two readings recorded this

  • serum osteocalcin

    no effect

    Furthermore, 1500 mg/day but not 2250 mg/day increases serum osteocalcin

    PMID 1422972 · one of two readings recorded this

  • serum parathyroid hormone (PTH)(1-84) during oral phosphate treatment

    increases, rose to a maximum of 36 and 33% in the 1500 and 2250 mg/day groups

    Not recorded as a finding: this platform holds no node for the endpoint

    Serum parathyroid hormone (PTH) rose significantly (P less than 0.05) during treatment to a maximum of 36 and 33% in the groups receiving 1500 and 2250 mg/day, respectively, whereas serum 1,25-dihydroxycholecalciferol remained unchanged.

    PMID 1422972 · one of two readings recorded this

  • serum parathyroid hormone (PTH) maximum rise

    increases, p = 0.05

    Serum parathyroid hormone (PTH) rose significantly (P less than 0.05) during treatment to a maximum of 36 and 33% in the groups receiving 1500 and 2250 mg/day, respectively

    PMID 1422972 · one of two readings recorded this

  • serum parathyroid hormone (PTH) maximum rise

    increases, p = 0.05

    Serum parathyroid hormone (PTH) rose significantly (P less than 0.05) during treatment to a maximum of 36 and 33% in the groups receiving 1500 and 2250 mg/day, respectively

    PMID 1422972 · one of two readings recorded this

  • serum phosphate, assay not stated in the abstract

    no effect

    Not recorded as a finding: the paper never states the instrument the node requires

    Urinary phosphate/creatinine ratio increased in a dose-dependent fashion during treatment (P less than 0.001), whereas no significant changes were seen in serum phosphate or serum calcium.

    PMID 1422972 · one of two readings recorded this

  • serum phosphate

    no effect

    no significant changes were seen in serum phosphate or serum calcium

    PMID 1422972 · one of two readings recorded this

  • urinary hydroxyproline/creatinine ratio

    no effect

    no significant changes were observed in urinary hydroxyproline/creatinine ratio, or serum bone alkaline phosphatase

    PMID 1422972 · one of two readings recorded this

  • urinary phosphate/creatinine ratio

    increases, p = 0.001

    Urinary phosphate/creatinine ratio increased in a dose-dependent fashion during treatment (P less than 0.001)

    PMID 1422972 · one of two readings recorded this

  • urine acidification over the monitored period

    no effect, n = 7

    In addition, urine acidification was not achieved over the time period when urine pH was monitored

    PMID 15570319 · one of two readings recorded this

  • urine pH measured three times a day (first morning, afternoon, evening samples) in patients with neurogenic bladder on clean intermittent catheterization, on versus off a phosphorus supplement

    no effect

    Not recorded as a finding: this platform holds no node for the endpoint

    There was no significant change in urine pH during the 2-week period when a patient was on phosphorus supplementation compared to when the patient was off supplementation.

    PMID 15570319 · one of two readings recorded this

  • urine pH measured three times a day in patients with neurogenic bladder on clean intermittent catheterization, on versus off a phosphorus supplement

    no effect

    Not recorded as a finding: this platform holds no node for the endpoint

    There was no significant change in urine pH during the 2-week period when a patient was on phosphorus supplementation compared to when the patient was off supplementation.

    PMID 15570319 · one of two readings recorded this

  • urine pH

    no effect, n = 7

    There was no significant change in urine pH during the 2-week period when a patient was on phosphorus supplementation compared to when the patient was off supplementation

    PMID 15570319 · one of two readings recorded this

  • LDL cholesterol fall

    decreases, p = 0.001

    SH administration was associated with a 10.5% +/- 9.4% and a 20.1% +/- 6.8% fall in total cholesterol (p < 0.05) and low-density Lipoprotein cholesterol (p < 0.001) in phase A

    PMID 16722024 · one of two readings recorded this

  • LDL cholesterol fall

    decreases, p = 0.001

    11.9% +/- 7.2% (p < 0.05) and 21.5% +/- 2.4% (p < 0.001), respectively, in phase B

    PMID 16722024 · one of two readings recorded this

  • reduction in serum phosphorus

    no effect

    by 1.18 +/- 0.07 mg/dL (0.38 +/- 0.03 mmol/L) with SH and by 1.25 +/- 0.15 mg/dL (0.40 +/- 0.05 mmol/L) with AH in phase A (p = NS)

    PMID 16722024 · one of two readings recorded this

  • reduction in serum phosphorus

    no effect

    by 1.35 +/- 0.25 mg/dL (0.43 +/- 0.08 mmol/L) with AH and by 1.23 +/- 0.80 mg/dL (0.39 +/- 0.25 mmol/L) with SH in phase B (p = NS)

    PMID 16722024 · one of two readings recorded this

  • serum lipid parameters

    no effect

    In both phases of the study, AH administration was not followed by a significant change in serum lipid parameters

    PMID 16722024 · one of two readings recorded this

  • total cholesterol fall

    decreases, p = 0.05

    SH administration was associated with a 10.5% +/- 9.4% and a 20.1% +/- 6.8% fall in total cholesterol (p < 0.05) and low-density Lipoprotein cholesterol (p < 0.001) in phase A

    PMID 16722024 · one of two readings recorded this

  • total cholesterol fall

    decreases, p = 0.05

    11.9% +/- 7.2% (p < 0.05) and 21.5% +/- 2.4% (p < 0.001), respectively, in phase B

    PMID 16722024 · one of two readings recorded this

  • association of iFGF23 with serum Pi

    decreases

    negative association was detected between iFGF23 and serum Pi, whereas positive association was observed between iPTH and serum Pi during the short period

    PMID 17063170 · one of two readings recorded this

  • association of iPTH with serum Pi

    increases

    negative association was detected between iFGF23 and serum Pi, whereas positive association was observed between iPTH and serum Pi during the short period

    PMID 17063170 · one of two readings recorded this

  • postprandial serum inorganic phosphate, intact FGF23, intact PTH, 1,25-dihydroxyvitamin D and calcium, and urinary Pi and Ca excretion up to 8 h after test meals containing 400, 800 or 1200 mg Pi

    increases

    Not recorded as a finding: the comparison was against another active treatment

    Serum Pi levels and urinary Pi excretion significantly increased within 1 h after P400 and P800 intake.

    PMID 17063170 · one of two readings recorded this

  • postprandial serum inorganic phosphate (Pi) and intact FGF23, urinary Pi excretion, up to 8 h after lunch containing 400, 800 or 1200 mg Pi

    increases

    Not recorded as a finding: the comparison was against another active treatment

    Serum Pi levels and urinary Pi excretion significantly increased within 1 h after P400 and P800 intake.

    PMID 17063170 · one of two readings recorded this

  • serum iFGF23 level

    increases

    Significant increase of iFGF23 was observed at 8 h after P1200 intake compared with both P400 and P800 intake

    PMID 17063170 · one of two readings recorded this

  • serum iFGF23 level

    no effect

    Serum iFGF23 levels slightly decreased up to 8 h after P400 intake and up to 6 h after P800 intake, but not changed in P1200 intake

    PMID 17063170 · one of two readings recorded this

  • serum iFGF23 level

    decreases

    Serum iFGF23 levels slightly decreased up to 8 h after P400 intake and up to 6 h after P800 intake, but not changed in P1200 intake

    PMID 17063170 · one of two readings recorded this

  • serum iFGF23 level

    decreases

    Serum iFGF23 levels slightly decreased up to 8 h after P400 intake and up to 6 h after P800 intake, but not changed in P1200 intake

    PMID 17063170 · one of two readings recorded this

  • serum iPTH level

    increases

    Serum iPTH levels at 1-2 and 4-6 h after P1200 intake was significantly higher than those of P400 intake

    PMID 17063170 · one of two readings recorded this

  • serum Pi level

    increases

    Serum Pi levels and urinary Pi excretion significantly increased within 1 h after P400 and P800 intake

    PMID 17063170 · one of two readings recorded this

  • serum Pi level

    increases

    Serum Pi levels and urinary Pi excretion significantly increased within 1 h after P400 and P800 intake

    PMID 17063170 · one of two readings recorded this

  • urinary Pi excretion

    increases

    Serum Pi levels and urinary Pi excretion significantly increased within 1 h after P400 and P800 intake

    PMID 17063170 · one of two readings recorded this

  • urinary Pi excretion

    increases

    Serum Pi levels and urinary Pi excretion significantly increased within 1 h after P400 and P800 intake

    PMID 17063170 · one of two readings recorded this

  • blood lactate concentration

    no effect, n = 6

    Heart rate, V (E), RER and blood lactate concentration were not significantly affected by SP loading

    PMID 17569583 · one of two readings recorded this

  • heart rate, minute ventilation, RER and blood lactate concentration during the time trial

    no effect

    Not recorded as a finding: no outcome nodes for these measures; the sentence names SP only in an agentless passive

    Heart rate, V (E), RER and blood lactate concentration were not significantly affected by SP loading.

    PMID 17569583 · one of two readings recorded this

  • heart rate

    no effect, n = 6

    Heart rate, V (E), RER and blood lactate concentration were not significantly affected by SP loading

    PMID 17569583 · one of two readings recorded this

  • mean power during 16.1 km time-trial

    increases, p = 0.05, n = 6

    After SP loading mean power was greater than for P and C (C, 322+/-15 W; P, 317+/-16 W; SP, 347+/-19 W; ANOVA, P<0.05)

    PMID 17569583 · one of two readings recorded this

  • mean power output over a self-paced 16.1 km time trial

    increases

    Not recorded as a finding: mean-power-output node is a fixed-duration maximal effort (Wingate type); a variable-duration self-paced trial is a near miss for that definition

    After SP loading mean power was greater than for P and C (C, 322+/-15 W; P, 317+/-16 W; SP, 347+/-19 W; ANOVA, P<0.05) and time to complete the 16.1 km was shorter than P, but not C (ANOVA, P<0.05).

    PMID 17569583 · one of two readings recorded this

  • mean power output, relative change SP versus P

    increases, n = 6

    mean changes were mean power output +9.8+/-8.0% (+/-95% confidence interval); time -3.0+/-2.9%

    PMID 17569583 · one of two readings recorded this

  • minute ventilation (V (E))

    no effect, n = 6

    Heart rate, V (E), RER and blood lactate concentration were not significantly affected by SP loading

    PMID 17569583 · one of two readings recorded this

  • oxygen uptake (V O(2))

    unclear, p = 0.07, n = 6

    There was a tendency towards higher V O(2) after SP loading (ANOVA, P = 0.07)

    PMID 17569583 · one of two readings recorded this

  • respiratory exchange ratio (RER)

    no effect, n = 6

    Heart rate, V (E), RER and blood lactate concentration were not significantly affected by SP loading

    PMID 17569583 · one of two readings recorded this

  • time to complete 16.1 km, relative change SP versus P

    decreases, n = 6

    mean changes were mean power output +9.8+/-8.0% (+/-95% confidence interval); time -3.0+/-2.9%

    PMID 17569583 · one of two readings recorded this

  • time to complete 16.1 km

    decreases, p = 0.05, n = 6

    time to complete the 16.1 km was shorter than P, but not C (ANOVA, P<0.05)

    PMID 17569583 · one of two readings recorded this

  • time to complete a laboratory 16.1 km cycling time trial, and mean power output over it, after tribasic dodecahydrate sodium phosphate 1 g four times daily for 6 days against lactose placebo and an unsupplemented control trial

    decreases

    Not recorded as a finding: the supporting sentence never names the compound

    After SP loading mean power was greater than for P and C (C, 322+/-15 W; P, 317+/-16 W; SP, 347+/-19 W; ANOVA, P<0.05) and time to complete the 16.1 km was shorter than P, but not C (ANOVA, P<0.05).

    PMID 17569583 · one of two readings recorded this

  • 24-h urinary phosphate excretion reduction

    no effect

    but the difference compared with placebo did not reach significance (64% vs. 31%)

    PMID 20631407 · one of two readings recorded this

  • 24-h urinary phosphate excretion reduction

    decreases, p = 0.0001

    Compared with the 1500-mg phosphorus diet, patients assigned to the 750-mg diet had greater reduction in 24-h urinary phosphate excretion (66% vs. 29%; P<0.0001)

    PMID 20631407 · one of two readings recorded this

  • 24-h urinary phosphate excretion reduction

    decreases, p = 0.0001

    Lanthanum-treated patients experienced a significant reduction in 24-h urinary phosphate excretion compared with baseline (64%; P<0.0001)

    PMID 20631407 · one of two readings recorded this

  • FGF23 levels

    increases

    FGF23 levels actually increased significantly in the 1500-mg diet plus placebo group

    PMID 20631407 · one of two readings recorded this

  • FGF23 levels

    no effect

    no group demonstrated a significant reduction in FGF23 levels

    PMID 20631407 · one of two readings recorded this

  • energy intake at laboratory meal, prolonged supplementation

    no effect, p = 0.581

    or prolonged supplementation with sodium phosphate (p = .581) compared with placebo

    PMID 22804972 · one of two readings recorded this

  • energy intake at laboratory meal

    no effect, p = 0.385

    no difference in energy intake at the laboratory meal after an acute dose (i.e., on Day 1; placebo 2,471 ± 919 kJ, phosphate 2,353 ± 987 kJ; p = .385)

    PMID 22804972 · one of two readings recorded this

  • VO(2peak)

    no effect, p = 0.483

    no difference in VO(2peak) with phosphate supplementation (placebo 52.6 ± 5.2 ml · kg(-1) · min(-1), phosphate 53.3 ± 6.1 ml · kg(-1) · min(-1); p = .483)

    PMID 22804972 · one of two readings recorded this

  • maximal oxygen uptake

    increases, n = 7

    Phosphate loading significantly increased maximal oxygen uptake from 4.77 +/- 0.29 to 5.18 +/- 0.25 l.min-1 and ventilatory anaerobic threshold from 3.74 +/- 0.28 to 4.18 +/- 0.14 l.min-1

    PMID 2355823 · one of two readings recorded this

  • hemoglobin

    increases, n = 7

    Resting and post-exercise 2,3-diphosphoglycerate values were decreased while hemoglobin values were elevated with phosphate ingestion

    PMID 2355823 · one of two readings recorded this

  • 2,3-diphosphoglycerate

    decreases, n = 7

    Resting and post-exercise 2,3-diphosphoglycerate values were decreased while hemoglobin values were elevated with phosphate ingestion

    PMID 2355823 · one of two readings recorded this

  • 2,3-diphosphoglycerate

    decreases, n = 7

    Resting and post-exercise 2,3-diphosphoglycerate values were decreased while hemoglobin values were elevated with phosphate ingestion

    PMID 2355823 · one of two readings recorded this

  • 5-mile run time

    no effect, n = 7

    Five-mile run times were nonsignificantly different between placebo and phosphate sessions

    PMID 2355823 · one of two readings recorded this

  • blood haemoglobin, venous samples before and after max and run sessions

    increases, hemoglobin values were elevated with phosphate ingestion

    Not recorded as a finding: blood-haemoglobin node exists but the sentence gives no significance statement and pools resting and post-exercise values in one sentence with 2,3-DPG; direction not anchored as a tested between-arm result

    Resting and post-exercise 2,3-diphosphoglycerate values were decreased while hemoglobin values were elevated with phosphate ingestion.

    PMID 2355823 · one of two readings recorded this

  • blood hemoglobin, resting and post-exercise, method not stated

    increases

    Not recorded as a finding: node blood-haemoglobin exists but the sentence states no significance and no method, and shares the sentence with 2,3-DPG; left out rather than claim an unqualified increase

    Resting and post-exercise 2,3-diphosphoglycerate values were decreased while hemoglobin values were elevated with phosphate ingestion.

    PMID 2355823 · one of two readings recorded this

  • mean oxygen uptake during the 5-mile performance run

    decreases, 3.87 +/- 0.3 to 3.80 +/- 0.3 l.min-1, significantly lower

    Not recorded as a finding: no_outcome_node: submaximal run oxygen uptake (running economy) has no outcome

    However, mean performance run oxygen uptake was significantly lower (3.87 +/- 0.3 to 3.80 +/- 0.3 l.min-1) with phosphate ingestion.

    PMID 2355823 · one of two readings recorded this

  • oxygen uptake during 5-mile performance run

    decreases, n = 7

    mean performance run oxygen uptake was significantly lower (3.87 +/- 0.3 to 3.80 +/- 0.3 l.min-1) with phosphate ingestion

    PMID 2355823 · one of two readings recorded this

  • oxygen uptake during the 5-mile performance run, l.min-1

    decreases, from 3.87 +/- 0.3 to 3.80 +/- 0.3 l.min-1, n = 7

    Not recorded as a finding: submaximal run oxygen cost, not VO2max; no outcome node

    However, mean performance run oxygen uptake was significantly lower (3.87 +/- 0.3 to 3.80 +/- 0.3 l.min-1) with phosphate ingestion.

    PMID 2355823 · one of two readings recorded this

  • red cell 2,3-diphosphoglycerate, resting and post-exercise

    decreases

    Not recorded as a finding: no outcome node for 2,3-diphosphoglycerate; sentence is also agentless about arms beyond 'phosphate ingestion' and gives no estimate

    Resting and post-exercise 2,3-diphosphoglycerate values were decreased while hemoglobin values were elevated with phosphate ingestion.

    PMID 2355823 · one of two readings recorded this

  • serum 2,3-diphosphoglycerate, resting and post-exercise

    decreases, values were decreased with phosphate ingestion

    Not recorded as a finding: no_outcome_node: no outcome for red cell or serum 2,3-diphosphoglycerate

    Resting and post-exercise 2,3-diphosphoglycerate values were decreased while hemoglobin values were elevated with phosphate ingestion.

    PMID 2355823 · one of two readings recorded this

  • serum phosphate, resting and post-exercise, assay not stated

    increases

    Not recorded as a finding: node serum-phosphate requires a colorimetric molybdate assay the abstract never states; also a manipulation check of the dosed compound

    Results revealed that placebo resting serum phosphate levels were mildly elevated and that phosphate loading significantly increased resting and post-exercise serum phosphate values.

    PMID 2355823 · one of two readings recorded this

  • serum phosphate, resting and post-exercise

    increases, significantly increased resting and post-exercise serum phosphate values

    Not recorded as a finding: no_outcome_node: no outcome for serum phosphate concentration

    Results revealed that placebo resting serum phosphate levels were mildly elevated and that phosphate loading significantly increased resting and post-exercise serum phosphate values.

    PMID 2355823 · one of two readings recorded this

  • serum phosphate

    increases, n = 7

    phosphate loading significantly increased resting and post-exercise serum phosphate values

    PMID 2355823 · one of two readings recorded this

  • serum phosphate

    increases, n = 7

    phosphate loading significantly increased resting and post-exercise serum phosphate values

    PMID 2355823 · one of two readings recorded this

  • serum phosphate

    unclear, n = 7

    placebo resting serum phosphate levels were mildly elevated

    PMID 2355823 · one of two readings recorded this

  • ventilatory anaerobic threshold, l.min-1 oxygen uptake during maximal running test

    increases, from 3.74 +/- 0.28 to 4.18 +/- 0.14 l.min-1

    Not recorded as a finding: no_outcome_node: no outcome for ventilatory anaerobic threshold

    Phosphate loading significantly increased maximal oxygen uptake from 4.77 +/- 0.29 to 5.18 +/- 0.25 l.min-1 and ventilatory anaerobic threshold from 3.74 +/- 0.28 to 4.18 +/- 0.14 l.min-1.

    PMID 2355823 · one of two readings recorded this

  • ventilatory anaerobic threshold, l.min-1

    increases, from 3.74 +/- 0.28 to 4.18 +/- 0.14 l.min-1, n = 7

    Not recorded as a finding: no outcome node for ventilatory anaerobic threshold

    Phosphate loading significantly increased maximal oxygen uptake from 4.77 +/- 0.29 to 5.18 +/- 0.25 l.min-1 and ventilatory anaerobic threshold from 3.74 +/- 0.28 to 4.18 +/- 0.14 l.min-1.

    PMID 2355823 · one of two readings recorded this

  • ventilatory anaerobic threshold

    increases, n = 7

    Phosphate loading significantly increased maximal oxygen uptake from 4.77 +/- 0.29 to 5.18 +/- 0.25 l.min-1 and ventilatory anaerobic threshold from 3.74 +/- 0.28 to 4.18 +/- 0.14 l.min-1

    PMID 2355823 · one of two readings recorded this

  • postprandial apolipoprotein B100

    decreases, p = 0.05

    phosphorus supplementation increased postprandial concentrations of apolipoprotein B48 (ApoB48) (p<0.05) and decreased that of apolipoprotein B100 (ApoB100) (p<0.05)

    PMID 25002136 · one of two readings recorded this

  • postprandial apolipoprotein B48

    increases, p = 0.05

    phosphorus supplementation increased postprandial concentrations of apolipoprotein B48 (ApoB48) (p<0.05) and decreased that of apolipoprotein B100 (ApoB100) (p<0.05)

    PMID 25002136 · one of two readings recorded this

  • postprandial insulin, NEFA and triglyceride

    no effect

    In the phosphorus (P) supplemented group, postprandial serum P increased (p=0.00), while changes in insulin, non-esterified fatty acids (NEFA) and triglyceride (TG) were not significantly different than that of placebo

    PMID 25002136 · one of two readings recorded this

  • postprandial serum phosphorus

    increases

    In the phosphorus (P) supplemented group, postprandial serum P increased (p=0.00), while changes in insulin, non-esterified fatty acids (NEFA) and triglyceride (TG) were not significantly different than that of placebo

    PMID 25002136 · one of two readings recorded this

  • postprandial triglyceride, 6-hour repeated-measures ANOVA, no fast-state sample

    no effect, not significantly different than placebo

    Not recorded as a finding: serum-triglycerides node requires a sample after a stated fast; this is postprandial, a near miss

    In the phosphorus (P) supplemented group, postprandial serum P increased (p=0.00), while changes in insulin, non-esterified fatty acids (NEFA) and triglyceride (TG) were not significantly different than that of placebo.

    PMID 25002136 · one of two readings recorded this

  • postprandial triglyceride, NEFA, insulin, ApoB48 and ApoB100 over 6 hours after a high-fat meal with 500 mg phosphorus or placebo

    no effect

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    In the phosphorus (P) supplemented group, postprandial serum P increased (p=0.00), while changes in insulin, non-esterified fatty acids (NEFA) and triglyceride (TG) were not significantly different than that of placebo.

    PMID 25002136 · one of two readings recorded this

  • mean power output in repeated-sprint test

    increases, p = 0.05

    the sodium phosphate group recorded significantly improved (P < 0.05) work and mean power output values in both the sprint (baseline, 259 kJ/719 W; day 1, 271 kJ/754 W; day 4, 271 kJ/753 W)

    PMID 25494032 · one of two readings recorded this

  • mean power output in repeated-sprint test

    increases, p = 0.05

    the sodium phosphate group recorded significantly improved (P < 0.05) work and mean power output values in both the sprint (baseline, 259 kJ/719 W; day 1, 271 kJ/754 W; day 4, 271 kJ/753 W)

    PMID 25494032 · one of two readings recorded this

  • mean power output in time-trial test

    increases

    time-trial (baseline, 225 kJ/374 W; day 1, 235 kJ/398 W; day 4, 236 kJ/393 W) aspects of the performance test post-loading

    PMID 25494032 · one of two readings recorded this

  • mean power output in time-trial test

    increases

    time-trial (baseline, 225 kJ/374 W; day 1, 235 kJ/398 W; day 4, 236 kJ/393 W) aspects of the performance test post-loading

    PMID 25494032 · one of two readings recorded this

  • power output

    no effect, p = 0.05

    In the placebo group, no differences (P > 0.05) in total work or power output were noted in response to supplementation

    PMID 25494032 · one of two readings recorded this

  • total work

    no effect, p = 0.05

    In the placebo group, no differences (P > 0.05) in total work or power output were noted in response to supplementation

    PMID 25494032 · one of two readings recorded this

  • work and mean power output in repeated 15 s sprints and 5 min time-trial efforts on an air-braked cycle ergometer, change from baseline at day 1 and day 4 post-loading

    increases

    Not recorded as a finding: the result compares a group with itself, not with a control

    Compared with baseline, the sodium phosphate group recorded significantly improved (P < 0.05) work and mean power output values in both the sprint (baseline, 259 kJ/719 W; day 1, 271 kJ/754 W; day 4, 271 kJ/753 W) and time-trial (baseline, 225 kJ/374 W; day 1, 235 kJ/398 W; day 4, 236 kJ/393 W) aspects of the performance test post-loading.

    PMID 25494032 · one of two readings recorded this

  • work and mean power output in repeated-sprint (4 sets of 6 x 15 s) and time-trial (2 x 5 min) cycling efforts on an air-braked ergometer, 1 and 4 days post-loading

    increases, work and mean power higher than baseline in the sodium phosphate group, e.g. sprint 719 W to 754 W on day 1

    Not recorded as a finding: the result compares a group with itself, not with a control

    Compared with baseline, the sodium phosphate group recorded significantly improved (P < 0.05) work and mean power output values in both the sprint (baseline, 259 kJ/719 W; day 1, 271 kJ/754 W; day 4, 271 kJ/753 W) and time-trial (baseline, 225 kJ/374 W; day 1, 235 kJ/398 W; day 4, 236 kJ/393 W) aspects of the performance test post-loading.

    PMID 25494032 · one of two readings recorded this

  • work in repeated-sprint test

    increases, p = 0.05

    the sodium phosphate group recorded significantly improved (P < 0.05) work and mean power output values in both the sprint (baseline, 259 kJ/719 W; day 1, 271 kJ/754 W; day 4, 271 kJ/753 W)

    PMID 25494032 · one of two readings recorded this

  • work in repeated-sprint test

    increases, p = 0.05

    the sodium phosphate group recorded significantly improved (P < 0.05) work and mean power output values in both the sprint (baseline, 259 kJ/719 W; day 1, 271 kJ/754 W; day 4, 271 kJ/753 W)

    PMID 25494032 · one of two readings recorded this

  • work in time-trial test

    increases

    time-trial (baseline, 225 kJ/374 W; day 1, 235 kJ/398 W; day 4, 236 kJ/393 W) aspects of the performance test post-loading

    PMID 25494032 · one of two readings recorded this

  • work in time-trial test

    increases

    time-trial (baseline, 225 kJ/374 W; day 1, 235 kJ/398 W; day 4, 236 kJ/393 W) aspects of the performance test post-loading

    PMID 25494032 · one of two readings recorded this

  • best sprint time, all sets

    decreases, p = 0.01

    best sprints were 0.13-0.23 and 0.15-0.20 s faster (~6% improvement; p < 0.01) after SP compared with placebo and BJ, respectively, for all sets

    PMID 26077126 · one of two readings recorded this

  • best sprint time, all sets

    decreases, p = 0.01

    best sprints were 0.13-0.23 and 0.15-0.20 s faster (~6% improvement; p < 0.01) after SP compared with placebo and BJ, respectively, for all sets

    PMID 26077126 · one of two readings recorded this

  • total and best sprint time in 6 x 20-m repeated-sprint sets of a simulated team-game circuit

    decreases

    Not recorded as a finding: this platform holds no node for the endpoint

    Specifically, total and best sprint times were faster after SP compared with placebo and BJ.

    PMID 26077126 · one of two readings recorded this

  • total and best sprint times of 6 x 20-m repeated-sprint sets at the start, half-time and end of a simulated team-game circuit

    decreases

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    Specifically, total and best sprint times were faster after SP compared with placebo and BJ.

    PMID 26077126 · one of two readings recorded this

  • total sprint time, overall across repeated-sprint sets

    decreases, p = 0.02

    3.25 and 3.12 s faster overall (~5% improvement) after SP compared with placebo and BJ, respectively (p = 0.02 for sets 1, 2 and overall

    PMID 26077126 · one of two readings recorded this

  • total sprint time, overall across repeated-sprint sets

    decreases, p = 0.02

    3.25 and 3.12 s faster overall (~5% improvement) after SP compared with placebo and BJ, respectively (p = 0.02 for sets 1, 2 and overall

    PMID 26077126 · one of two readings recorded this

  • total sprint time, repeated-sprint set 2

    decreases, p = 0.05

    total sprint times were 0.48 s faster after SP + BJ compared with placebo (set 2; p = 0.05, ~2% improvement)

    PMID 26077126 · one of two readings recorded this

  • baseline age

    n = 26

    The mean age was 36.67 (9.76) years in the placebo group and 34.04 (11.24) years in the phosphorus group

    PMID 26690287 · one of two readings recorded this

  • baseline age

    n = 21

    The mean age was 36.67 (9.76) years in the placebo group and 34.04 (11.24) years in the phosphorus group

    PMID 26690287 · one of two readings recorded this

  • baseline glomerular filtration rate

    n = 26

    a mean of 114.14 (10.19) ml min−1 per 1.73 m2 and 112.24 (13.46) ml min−1 per 1.73 m2 for the placebo and phosphorus groups, respectively

    PMID 26690287 · one of two readings recorded this

  • baseline glomerular filtration rate

    n = 21

    a mean of 114.14 (10.19) ml min−1 per 1.73 m2 and 112.24 (13.46) ml min−1 per 1.73 m2 for the placebo and phosphorus groups, respectively

    PMID 26690287 · one of two readings recorded this

  • BMI, between-group difference in change

    decreases, p = 0.01, n = 47

    the changes in BMI of the placebo group (0.42 kg m−2, 95% CI 0.05 to 0.78) was significantly different (P=0.01) than that of the phosphorus group (−0.24 kg m−2, 95% CI −0.59 to 0.12)

    PMID 26690287 · one of two readings recorded this

  • BMI, change from baseline

    decreases, n = 26

    the changes in BMI of the placebo group (0.42 kg m−2, 95% CI 0.05 to 0.78) was significantly different (P=0.01) than that of the phosphorus group (−0.24 kg m−2, 95% CI −0.59 to 0.12)

    PMID 26690287 · one of two readings recorded this

  • BMI, change from baseline

    increases, n = 21

    the changes in BMI of the placebo group (0.42 kg m−2, 95% CI 0.05 to 0.78) was significantly different (P=0.01) than that of the phosphorus group (−0.24 kg m−2, 95% CI −0.59 to 0.12)

    PMID 26690287 · one of two readings recorded this

  • body mass index change over 12 weeks, from measured weight and height

    BMI change placebo 0.42 vs phosphorus -0.24 kg/m2, significantly different, p = 0.01

    Not recorded as a finding: the sentence gives no direction in words; the arm changes are signed estimates only

    Consequently, the changes in BMI of the placebo group (0.42 kg m−2, 95% CI 0.05 to 0.78) was significantly different (P=0.01) than that of the phosphorus group (−0.24 kg m−2, 95% CI −0.59 to 0.12).

    PMID 26690287 · one of two readings recorded this

  • body mass index from measured height and weight, change from baseline to 12 weeks

    placebo +0.42 kg/m2 (95% CI 0.05 to 0.78) against phosphorus -0.24 kg/m2 (95% CI -0.59 to 0.12), p = 0.01

    Not recorded as a finding: Direction is carried only as signed estimates, 'significantly different' with no direction word

    Consequently, the changes in BMI of the placebo group (0.42 kg m−2, 95% CI 0.05 to 0.78) was significantly different (P=0.01) than that of the phosphorus group (−0.24 kg m−2, 95% CI −0.59 to 0.12).

    PMID 26690287 · one of two readings recorded this

  • body weight, between-group difference in change

    decreases, p = 0.01, n = 47

    These variations resulted in a significant difference (P=0.01) in the changes in body weight between the two groups

    PMID 26690287 · one of two readings recorded this

  • body weight, change from baseline

    decreases, n = 26

    that of the phosphorus group decreased by 0.65 kg (95% CI −1.69 to 0.40)

    PMID 26690287 · one of two readings recorded this

  • body weight, change from baseline

    increases, n = 21

    Body weight of the placebo group increased significantly from baseline by 1.13 kg (95% confidence interval (CI) 0.19 to 2.06)

    PMID 26690287 · one of two readings recorded this

  • body weight change over 12 weeks, calibrated Seca balance

    between-group difference in body-weight change significant, p = 0.01

    Not recorded as a finding: the between-group sentence says only that the difference was significant and names neither the compound nor a direction; the sentence naming the direction describes two within-arm changes, one of them non-significant

    These variations resulted in a significant difference (P=0.01) in the changes in body weight between the two groups.

    PMID 26690287 · one of two readings recorded this

  • body weight on a calibrated Seca balance, change from baseline to 12 weeks

    decreases, phosphorus group -0.65 kg (95% CI -1.69 to 0.40) against placebo +1.13 kg (95% CI 0.19 to 2.06)

    Not recorded as a finding: The only sentence naming the phosphorus group reports a within-arm change; the between-group contrast is in the next sentence, which does not name the compound

    Body weight of the placebo group increased significantly from baseline by 1.13 kg (95% confidence interval (CI) 0.19 to 2.06), whereas that of the phosphorus group decreased by 0.65 kg (95% CI −1.69 to 0.40).

    PMID 26690287 · one of two readings recorded this

  • HOMA-IR, change

    unclear, n = 47

    Serum levels of insulin and HOMA-IR were similar between the two treatments at baseline and at 12 weeks, although a mild but significant difference was detected in their changes

    PMID 26690287 · one of two readings recorded this

  • hunger, change

    decreases, n = 47

    The changes in several parameters of subjective appetite scores were found to decrease as the experiment progressed including that of appetite, quantity of food to reach fullness, hunger and number of snacks

    PMID 26690287 · one of two readings recorded this

  • number of snacks, change

    decreases, n = 47

    changes in appetite, quantity of food to reach fullness, taste of food and number of snacks were significantly reduced in the phosphorus group as compared with the placebo

    PMID 26690287 · one of two readings recorded this

  • quantity of food to reach fullness, change

    decreases, n = 47

    changes in appetite, quantity of food to reach fullness, taste of food and number of snacks were significantly reduced in the phosphorus group as compared with the placebo

    PMID 26690287 · one of two readings recorded this

  • serum C-reactive protein

    no effect, n = 47

    Placebo or phosphorus treatment for 12 weeks did not affect serum levels of phosphorus, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, glucose and C-reactive protein

    PMID 26690287 · one of two readings recorded this

  • serum glucose

    no effect, n = 47

    Placebo or phosphorus treatment for 12 weeks did not affect serum levels of phosphorus, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, glucose and C-reactive protein

    PMID 26690287 · one of two readings recorded this

  • serum HDL cholesterol

    no effect, n = 47

    Placebo or phosphorus treatment for 12 weeks did not affect serum levels of phosphorus, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, glucose and C-reactive protein

    PMID 26690287 · one of two readings recorded this

  • serum insulin, change

    unclear, n = 47

    Serum levels of insulin and HOMA-IR were similar between the two treatments at baseline and at 12 weeks, although a mild but significant difference was detected in their changes

    PMID 26690287 · one of two readings recorded this

  • serum LDL cholesterol

    no effect, n = 47

    Placebo or phosphorus treatment for 12 weeks did not affect serum levels of phosphorus, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, glucose and C-reactive protein

    PMID 26690287 · one of two readings recorded this

  • serum phosphorus, total cholesterol, LDL, HDL, triglyceride, glucose and C-reactive protein (Vitros 350), change over 12 weeks

    no effect, no estimate stated

    Not recorded as a finding: One sentence covers both treatments as a within-arm statement; it is not a between-arm contrast

    Placebo or phosphorus treatment for 12 weeks did not affect serum levels of phosphorus, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, glucose and C-reactive protein.

    PMID 26690287 · one of two readings recorded this

  • serum phosphorus, total, LDL and HDL cholesterol, triglyceride, glucose and C-reactive protein, Vitros 350 analyser, fasting, 12 weeks

    no effect

    Not recorded as a finding: one sentence names both arms together and reports no effect of each treatment, not a between-arm contrast, and covers seven endpoints at once, so it cannot anchor one claim

    Placebo or phosphorus treatment for 12 weeks did not affect serum levels of phosphorus, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, glucose and C-reactive protein.

    PMID 26690287 · one of two readings recorded this

  • serum phosphorus

    no effect, n = 47

    Placebo or phosphorus treatment for 12 weeks did not affect serum levels of phosphorus, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, glucose and C-reactive protein

    PMID 26690287 · one of two readings recorded this

  • serum total cholesterol

    no effect, n = 47

    Placebo or phosphorus treatment for 12 weeks did not affect serum levels of phosphorus, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, glucose and C-reactive protein

    PMID 26690287 · one of two readings recorded this

  • serum triglyceride

    no effect, n = 47

    Placebo or phosphorus treatment for 12 weeks did not affect serum levels of phosphorus, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, glucose and C-reactive protein

    PMID 26690287 · one of two readings recorded this

  • subjective appetite, change

    decreases, n = 47

    changes in appetite, quantity of food to reach fullness, taste of food and number of snacks were significantly reduced in the phosphorus group as compared with the placebo

    PMID 26690287 · one of two readings recorded this

  • subjective appetite questionnaire scores (appetite, quantity of food to reach fullness, taste of food, number of snacks), questionnaire after Wilson et al.

    decreases

    Not recorded as a finding: no outcome node for a subjective appetite questionnaire

    However, changes in appetite, quantity of food to reach fullness, taste of food and number of snacks were significantly reduced in the phosphorus group as compared with the placebo as shown in Table 3.

    PMID 26690287 · one of two readings recorded this

  • subjective appetite scores (appetite, quantity of food to reach fullness, taste of food, number of snacks), questionnaire after Wilson et al.

    decreases, significantly reduced in the phosphorus group against placebo (Table 3)

    Not recorded as a finding: No node for a subjective appetite questionnaire score

    However, changes in appetite, quantity of food to reach fullness, taste of food and number of snacks were significantly reduced in the phosphorus group as compared with the placebo as shown in Table 3.

    PMID 26690287 · one of two readings recorded this

  • taste of food, change

    decreases, n = 47

    changes in appetite, quantity of food to reach fullness, taste of food and number of snacks were significantly reduced in the phosphorus group as compared with the placebo

    PMID 26690287 · one of two readings recorded this

  • waist circumference, between-group difference in change

    decreases, p = 0.001, n = 47

    waist circumference of the phosphorus group was significantly reduced by 3.62 cm (95% CI −4.90 to −2.33), and this reduction was significantly different (P<0.001) from the small increase of 0.38 cm (95% CI −0.44 to 1.20) in the waist circumference of the placebo group

    PMID 26690287 · one of two readings recorded this

  • waist circumference, change from baseline

    decreases, n = 26

    waist circumference of the phosphorus group was significantly reduced by 3.62 cm (95% CI −4.90 to −2.33), and this reduction was significantly different (P<0.001) from the small increase of 0.38 cm (95% CI −0.44 to 1.20) in the waist circumference of the placebo group

    PMID 26690287 · one of two readings recorded this

  • waist circumference, change from baseline

    no effect, n = 21

    waist circumference of the phosphorus group was significantly reduced by 3.62 cm (95% CI −4.90 to −2.33), and this reduction was significantly different (P<0.001) from the small increase of 0.38 cm (95% CI −0.44 to 1.20) in the waist circumference of the placebo group

    PMID 26690287 · one of two readings recorded this

  • Acetivibrio genus and Coriobacteriaceae family abundance

    decreases, p = 0.05

    Abundance of the genus Acetivibio and of the family Coriobacteriaceae were significantly lower in men after eight weeks of P1000/Ca500 intervention when compared to P1000/Ca0 intervention (p < 0.05)

    PMID 29452584 · one of two readings recorded this

  • Bifidobacterium OTU abundance

    decreases, p = 0.04

    The OTUs belonging to Bifidobacterium genus were significantly less abundant in faeces of men of the P1000/Ca1000 intervention compared to the faeces of men of the P1000/Ca500 group (p = 0.04)

    PMID 29452584 · one of two readings recorded this

  • Clostridium XVIII abundance

    increases, p = 0.04

    Clostridium XVIII was significantly more abundant in men of the P1000/Ca1000 intervention group compared to men of the P1000/Ca500 (p = 0.04) and P1000/Ca0 (p = 0.04) groups

    PMID 29452584 · one of two readings recorded this

  • Clostridium XVIII abundance

    increases, p = 0.04

    Clostridium XVIII was significantly more abundant in men of the P1000/Ca1000 intervention group compared to men of the P1000/Ca500 (p = 0.04) and P1000/Ca0 (p = 0.04) groups

    PMID 29452584 · one of two readings recorded this

  • faecal fat

    no effect

    8 weeks | 5.5 ± 3.1 | 5.6 ± 2.5 | 4.0 ± 2.3

    PMID 29452584 · one of two readings recorded this

  • faecal fat

    Placebo | 5.9 ± 2.8 | 5.6 ± 3.2 | 4.1 ± 1.7

    PMID 29452584 · one of two readings recorded this

  • faecal pH value

    decreases

    In the whole study collective and in male subjects, the pH value decreased significantly due to P1000/Ca1000 intervention after eight weeks compared to placebo

    PMID 29452584 · one of two readings recorded this

  • faecal pH value

    decreases

    8 weeks | 6.5 ± 0.5 | 6.3 ± 0.5 | 6.5* ± 0.6

    PMID 29452584 · one of two readings recorded this

  • faecal pH value

    Placebo | 6.7 ± 0.7 | 6.6 ± 0.5 | 7.0 ± 0.7

    PMID 29452584 · one of two readings recorded this

  • faecal short-chain fatty acids (total SCFA, acetate) by gas chromatography, faecal fat by Soxhlet extraction, faecal water cyto- and genotoxicity in HT29 cells

    no effect

    Not recorded as a finding: this platform holds no node for the endpoint

    Faecal fat concentrations did not change significantly due to the interventions (Table 1).

    PMID 29452584 · one of two readings recorded this

  • faecal water genotoxic activity before intervention

    increases

    FW obtained from P1000/Ca0 subjects showed significantly higher genotoxic activity before the intervention compared to those from the P1000/Ca1000 group

    PMID 29452584 · one of two readings recorded this

  • genotoxic activity of faecal water (tail intensity)

    no effect

    The interventions with phosphorus did not significantly affect the TI as a marker for genotoxic activity of the FW

    PMID 29452584 · one of two readings recorded this

  • gut microbial community structure (Bray-Curtis)

    modulates, p = 0.01

    men of the P1000/Ca1000 intervention had a significantly different gut microbial community compared to the men of the P1000/Ca0 (R = 0.778, p = 0.01) and the P1000/Ca500 groups (R = 0.593, p = 0.01)

    PMID 29452584 · one of two readings recorded this

  • gut microbial community structure (Bray-Curtis)

    modulates, p = 0.01

    men of the P1000/Ca1000 intervention had a significantly different gut microbial community compared to the men of the P1000/Ca0 (R = 0.778, p = 0.01) and the P1000/Ca500 groups (R = 0.593, p = 0.01)

    PMID 29452584 · one of two readings recorded this

  • HT29 cell vitality after faecal water incubation

    After incubation with FW, vitality of the HT29 cells ranged on average between 73 and 83%

    PMID 29452584 · one of two readings recorded this

  • HT29 cell vitality after faecal water incubation

    increases

    For the P1000/Ca1000 intervention group, incubation of HT29 cells with FW from the eight-week time-point resulted in a significantly higher vitality of the cells compared to placebo

    PMID 29452584 · one of two readings recorded this

  • OTU2 (butyrate-producing bacterium) abundance

    increases, p = 0.01

    OTU2, a butyrate-producing bacterium, was significantly more abundant in men of the P1000/Ca0 intervention group compared to the men with P1000/Ca1000 supplementation (p = 0.01)

    PMID 29452584 · one of two readings recorded this

  • OTU4 (Clostridium XVIII-related) abundance

    increases, p = 0.04

    OTU4, an uncultured bacterium related to Clostridium XVIII, was significantly more abundant in the men of P1000/Ca1000 intervention group compared to P1000/Ca500 (p = 0.03) and P1000/Ca0 (p = 0.04)

    PMID 29452584 · one of two readings recorded this

  • OTU4 (Clostridium XVIII-related) abundance

    increases, p = 0.03

    OTU4, an uncultured bacterium related to Clostridium XVIII, was significantly more abundant in the men of P1000/Ca1000 intervention group compared to P1000/Ca500 (p = 0.03) and P1000/Ca0 (p = 0.04)

    PMID 29452584 · one of two readings recorded this

  • tail intensity, negative control

    PBS (negative control) caused no genotoxic damages (TI 7 ± 2%)

    PMID 29452584 · one of two readings recorded this

  • tail intensity of faecal water

    mean TI for all subjects 25 ± 13%

    PMID 29452584 · one of two readings recorded this

  • tail intensity, positive control

    H2O2 caused strong genotoxic effects (TI 59 ± 15%)

    PMID 29452584 · one of two readings recorded this

  • total SCFA, acetate, propionate and butyrate

    no effect

    Considering men and women together, the interventions did not affect the concentrations of total SCFA or the concentrations of the main SCFA acetate, propionate and butyrate compared to placebo

    PMID 29452584 · one of two readings recorded this

  • total short-chain fatty acids and acetate

    increases

    acetate and total SCFA concentrations were significantly higher in the P1000/Ca1000 group compared to the P1000/Ca0 group after eight weeks, but only in male subjects

    PMID 29452584 · one of two readings recorded this

  • total short-chain fatty acids and acetate

    increases

    Certainly, concentrations of total SCFA and acetate were significantly higher after eight weeks of P1000/Ca500 supplementation compared to the P1000/Ca0

    PMID 29452584 · one of two readings recorded this

  • 20 km time-trial completion time

    no effect, n = 20

    There were also no effects of supplementation on time-trial performance (placebo: 32.8 ± 2.2 min; SP: 32.8 ± 2.3 min)

    PMID 29985679 · one of two readings recorded this

  • minute ventilation during the 20 km time trial, expired-air monitoring

    increases, mean difference 3.81 L/min, 95% CI 0.16 to 7.46

    Not recorded as a finding: no outcome node for minute ventilation

    Nevertheless, relative to placebo, SP increased V̇E (mean difference: 3.81 L·min-1; 95% confidence interval: [0.16, 7.46 L·min-1]), RER (mean difference: 0.020; 95% confidence interval: [0.004, 0.036]), and RPE (mean difference: 0.39; 95% confidence interval: [0.04, 0.73]) during time trials, as well as post time-trial blood lactate concentration (mean difference: 1.06 mmol·L-1; 95% confidence interval: [0.31, 1.80 mmol·L-1]).

    PMID 29985679 · one of two readings recorded this

  • minute ventilation (VE) during time trial

    increases, n = 20

    (mean difference: 3.81 L·min-1; 95% confidence interval: [0.16, 7.46 L·min-1])

    PMID 29985679 · one of two readings recorded this

  • physiological responses during submaximal cycling at 65% VO2max (VO2, VE, RER, heart rate, RPE, lactate)

    no effect, p = 0.05, n = 20

    There were no effects (p ≥ .05) of supplementation on physiological responses during cycling

    PMID 29985679 · one of two readings recorded this

  • post time-trial blood lactate concentration, capillary sample

    increases, mean difference 1.06 mmol/L, 95% CI 0.31 to 1.80

    Not recorded as a finding: no outcome node for blood lactate concentration

    Nevertheless, relative to placebo, SP increased V̇E (mean difference: 3.81 L·min-1; 95% confidence interval: [0.16, 7.46 L·min-1]), RER (mean difference: 0.020; 95% confidence interval: [0.004, 0.036]), and RPE (mean difference: 0.39; 95% confidence interval: [0.04, 0.73]) during time trials, as well as post time-trial blood lactate concentration (mean difference: 1.06 mmol·L-1; 95% confidence interval: [0.31, 1.80 mmol·L-1]).

    PMID 29985679 · one of two readings recorded this

  • post time-trial blood lactate concentration

    increases, n = 20

    blood lactate concentration (mean difference: 1.06 mmol·L-1; 95% confidence interval: [0.31, 1.80 mmol·L-1])

    PMID 29985679 · one of two readings recorded this

  • rating of perceived exertion (RPE) during time trial

    increases, n = 20

    (mean difference: 0.39; 95% confidence interval: [0.04, 0.73])

    PMID 29985679 · one of two readings recorded this

  • ratings of perceived exertion (RPE) during a 20 km cycling time trial; also 20 km time-trial completion time, minute ventilation, RER and post time-trial blood lactate

    increases, RPE mean difference 0.39, 95% CI [0.04, 0.73], SP relative to placebo

    Not recorded as a finding: the supporting sentence never names the compound

    Nevertheless, relative to placebo, SP increased V̇E (mean difference: 3.81 L·min-1; 95% confidence interval: [0.16, 7.46 L·min-1]), RER (mean difference: 0.020; 95% confidence interval: [0.004, 0.036]), and RPE (mean difference: 0.39; 95% confidence interval: [0.04, 0.73]) during time trials, as well as post time-trial blood lactate concentration (mean difference: 1.06 mmol·L-1; 95% confidence interval: [0.31, 1.80 mmol·L-1]).

    PMID 29985679 · one of two readings recorded this

  • respiratory exchange ratio during the 20 km time trial

    increases, mean difference 0.020, 95% CI 0.004 to 0.036

    Not recorded as a finding: no outcome node for respiratory exchange ratio

    Nevertheless, relative to placebo, SP increased V̇E (mean difference: 3.81 L·min-1; 95% confidence interval: [0.16, 7.46 L·min-1]), RER (mean difference: 0.020; 95% confidence interval: [0.004, 0.036]), and RPE (mean difference: 0.39; 95% confidence interval: [0.04, 0.73]) during time trials, as well as post time-trial blood lactate concentration (mean difference: 1.06 mmol·L-1; 95% confidence interval: [0.31, 1.80 mmol·L-1]).

    PMID 29985679 · one of two readings recorded this

  • respiratory exchange ratio (RER) during time trial

    increases, n = 20

    (mean difference: 0.020; 95% confidence interval: [0.004, 0.036])

    PMID 29985679 · one of two readings recorded this

  • postprandial energy expenditure and substrate oxidation, ventilated hood indirect calorimetry for 240 min

    increases

    Not recorded as a finding: this platform holds no node for the endpoint

    Phosphorus ingestion with a meal increased the postprandial energy expenditure of both lean and obese individuals (P < 0.001), although in different patterns.

    PMID 30153580 · one of two readings recorded this

  • postprandial energy expenditure over 240 min, ventilated hood indirect calorimetry

    increases

    Not recorded as a finding: this platform holds no node for the endpoint

    Phosphorus ingestion with a meal increased the postprandial energy expenditure of both lean and obese individuals (P < 0.001), although in different patterns.

    PMID 30153580 · one of two readings recorded this

  • postprandial energy expenditure

    increases, p = 0.001, n = 8

    Phosphorus ingestion with a meal increased the postprandial energy expenditure of both lean and obese individuals (P < 0.001)

    PMID 30153580 · one of two readings recorded this

  • postprandial energy expenditure

    increases, p = 0.001, n = 7

    Phosphorus ingestion with a meal increased the postprandial energy expenditure of both lean and obese individuals (P < 0.001)

    PMID 30153580 · one of two readings recorded this

  • respiratory quotient

    decreases, n = 8

    Alterations in postprandial substrate oxidation was highly noticeable from time 120 min onward, where phosphorus-treated lean participants exhibited a significant decrease in respiratory quotient

    PMID 30153580 · one of two readings recorded this

  • postprandial energy expenditure and substrate oxidation every 30 min for 4 h, ventilated hood indirect calorimetry

    increases, p = 0.005

    Not recorded as a finding: this platform holds no node for the endpoint

    NPr and HPr meals had similar postprandial energy expenditure and this was significantly increased (P = 0.005) by P ingestion.

    PMID 30509638 · one of two readings recorded this

  • postprandial energy expenditure every 30 min for 4 h, ventilated hood indirect calorimetry

    increases, p = 0.005

    Not recorded as a finding: this platform holds no node for the endpoint

    NPr and HPr meals had similar postprandial energy expenditure and this was significantly increased (P = 0.005) by P ingestion.

    PMID 30509638 · one of two readings recorded this

  • postprandial energy expenditure

    increases, p = 0.005, n = 24

    NPr and HPr meals had similar postprandial energy expenditure and this was significantly increased (P = 0.005) by P ingestion

    PMID 30509638 · one of two readings recorded this

  • diastolic blood pressure

    unclear

    Four studies found a significant inverse association with diastolic BP and 10 no significant associations

    PMID 31051505 · one of two readings recorded this

  • incident hypertension, highest vs lowest quintile of phosphorus intake

    decreases

    HR: 0.86 (95% CI: 0.75, 0.98); HR: 0.83 (95% CI: 0.68, 1.02); and HR: 0.75 (95% CI: 0.45, 1.27)

    PMID 31051505 · one of two readings recorded this

  • incident hypertension, highest vs lowest quintile of phosphorus intake

    decreases

    HR: 0.86 (95% CI: 0.75, 0.98); HR: 0.83 (95% CI: 0.68, 1.02); and HR: 0.75 (95% CI: 0.45, 1.27)

    PMID 31051505 · one of two readings recorded this

  • incident hypertension, highest vs lowest quintile of phosphorus intake

    no effect

    HR: 0.86 (95% CI: 0.75, 0.98); HR: 0.83 (95% CI: 0.68, 1.02); and HR: 0.75 (95% CI: 0.45, 1.27)

    PMID 31051505 · one of two readings recorded this

  • systolic blood pressure

    unclear

    Two studies found a significant positive association of dietary phosphorus with systolic BP, 4 a significant inverse association, and 8 no significant association

    PMID 31051505 · one of two readings recorded this

  • C-terminal fibroblast growth factor 23 (cFGF23)

    no effect, n = 34

    Dietary phosphorus intake was not related to cFGF23

    PMID 33427559 · one of two readings recorded this

  • intact fibroblast growth factor 23 (iFGF23)

    increases, p = 0.001, n = 34

    an increase in iFGF23 of 5.0% (95% CI, 2.0-8.0, p = .001)

    PMID 33427559 · one of two readings recorded this

  • intact parathyroid hormone (iPTH)

    increases, p = 0.01, n = 34

    an increase in iPTH of 5.4% (95% CI, 1.4-9.3, p = .01)

    PMID 33427559 · one of two readings recorded this

  • serum calcium

    decreases, p = 0.01, n = 34

    a decrease in serum calcium of 0.06 mg/dL (95% CI, -0.11 to -0.01, p = .01)

    PMID 33427559 · one of two readings recorded this

  • cardiac output (Q) at the given workloads

    no effect, n = 20

    There were no statistically significant changes in cardiac output (Q) at the given workloads (Table 2)

    PMID 34684557 · one of two readings recorded this

  • gross efficiency at workloads below lactate threshold, work accomplished over energy expended from VO2 and RER

    no effect

    Not recorded as a finding: no outcome node for gross efficiency

    There were no statistically significant changes in GE and RER at the given workloads after SP supplementation or placebo ingestion (Table 3).

    PMID 34684557 · one of two readings recorded this

  • gross efficiency (GE) at the given workloads

    no effect, n = 20

    There were no statistically significant changes in GE and RER at the given workloads after SP supplementation or placebo ingestion (Table 3)

    PMID 34684557 · one of two readings recorded this

  • heart rate at submaximal workloads below lactate threshold, breath-by-breath gas analyser

    decreases, HR at LT-2 and LT-1 decreased 3.9% (d = 0.36) and 3.4% (d = 0.38)

    Not recorded as a finding: no outcome node for submaximal heart rate

    The post-hoc Tukey test showed that HRLT−2 and HRLT−1 significantly (p < 0.01) decreased due to SP supplementation by 3.9% (d = 0.36) and 3.4% (d = 0.38), respectively.

    PMID 34684557 · one of two readings recorded this

  • hematocrit (Hct)

    no effect, n = 20

    There were no statistically significant changes in Hct (S1 vs. S2: SP 43.6 ± 0.6 vs. 43.1 ± 0.5%; Pl 44.1 ± 0.5 vs. 43.3 ± 0.5%)

    PMID 34684557 · one of two readings recorded this

  • hematocrit (Hct)

    no effect, n = 20

    There were no statistically significant changes in Hct (S1 vs. S2: SP 43.6 ± 0.6 vs. 43.1 ± 0.5%; Pl 44.1 ± 0.5 vs. 43.3 ± 0.5%)

    PMID 34684557 · one of two readings recorded this

The whole record — 318 rows